Cellect Biotechnology Ltd. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
Cellect Biotechnology Ltd. announced that it has treated the first blood cancer patient in the recently initiated Phase I/II trial of its stem cell technology ApoGraft™. Cellect CEO, Shai Yarkoni commented, “ApoGraft™ has been proven to be effective in assisting successful stem cells transplants and preventing GvHD during our animal studies.” Read the full article.
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. It also develops innovative technology which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar-Saba, Israel. [Source: MarketWatch]
Company Website: http://cellect.co